Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)
Not yet recruiting
- Conditions
- Coronary Heart DiseaseElderly PatientsDrug TherapyClinical Outcomes
- Registration Number
- NCT05246722
- Lead Sponsor
- Beijing Anzhen Hospital
- Brief Summary
A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 15000
Inclusion Criteria
- Informed consent has been signed
- Patients diagnosed in our hospital with coronary heart disease
- Age ≥65 years
Exclusion Criteria
- Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
- Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method main adverse cardiovascular and cerebrovascular events (MACCE) up to 3 years MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization
- Secondary Outcome Measures
Name Time Method Adverse drug reaction up to 3 years Adverse drug reaction will be defined as any adverse reactions in the patients
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie drug therapy efficacy in elderly coronary heart disease patients?
How does pharmacotherapy in NCT05246722 compare to standard-of-care treatments for geriatric CHD?
Which biomarkers are associated with favorable clinical outcomes in elderly CHD patients receiving drug therapy?
What adverse events are commonly observed in elderly patients with coronary heart disease undergoing pharmacotherapy?
Are there combination approaches or competitor drugs showing improved outcomes in elderly coronary artery disease populations?